Lupus

Interventions for patients with systemic lupus erythematosus (SLE) need to address physician/patient communication to improve health outcomes, according to Dr. Maheswaranathan.

New late-breaking data from ACR 2021 show the mRNA vaccine may differ in patients dependent on their disease.

Patients who are treated with B cell depletion therapies show that their B cell count at time of vaccination can impact their COVID-19 antibody response.

Lower health literacy has been found to be associated with worsened health outcomes for patients with systemic lupus erythematosus (SLE).

Kyriakos A. Kirou, MD, DSc, FACP, explains the key findings of his upcoming ACR presentation, “COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine.”

"The primary efficacy endpoint was the proportion of patients with disease control without other immunosuppressants and prednisone-equivalent dose of ≤5 mg/day at week 52," Aranow stated.

In this video interview, Dr. Jing Cui explains what the next steps could be for the risk prediction models of systemic lupus erythematosus.

In this video interview, Dr. Edigin talks about the importance of outpatient care in reducing hospitalizations for SLE flare.

Research presented by Dr. Jing Cui at ACR 2021 Convergence identified significant risk factors for systemic lupus erythematosus in a risk prediction model study.

Research results shows that while overall hospitalization for SLE flare decreased, it increased among African American patients.

Dr. Jing Cui speaks about how she examined lifestyle and environmental factors as well as genetic risk to assess risk of systemic lupus erythematosus.

In this interview, Dr. Edigin speaks about his longitudinal trend analysis that showed a decrease in SLE flare hospitalizations over the last 20 years.

Jean Liew, MD, MS, discusses her upcoming ACR Convergence presentation entitled, “SARS-CoV-2 Infections Among Vaccinated Individuals with Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Provider Registry."

“Systemic lupus erythematosus is a chronic inflammatory autoimmune disease where a variety of organ complications contribute to an increased risk of premature mortality,” investigators stated.

Comprehensive insight on the treatment armamentarium for systemic lupus erythematous and nuances in selecting optimal therapy.

Approximately a third of systemic lupus erythematosus patients experience ocular involvement, which may be linked to disease pathophysiology.

An overview of systemic lupus erythematous including possible causes, prevalence, symptomology, diagnosis, and the goals of therapy.

Investigators analyzed the potential beneficial effect of hydroxychloroquine to prevent COVID-19 infection in patients with rheumatic disease.

Veena Joy, MS, discusses Thermo Scientific’s recent FDA approval of their EliA SmDP-S test, which aides in the diagnosis of Systemic Lupus Erythematosus (SLE).

COVID-19 has added an additional level of complexity for patients with rheumatic disease who wish to become pregnant.

Results show a significantly higher risk of death and combined poor outcomes compared with patients without lupus and both with and without other comorbidities.

Patients with rheumatic disease reported significant employment status changes, which may imply issues with healthcare access, affordable medication, mental health concerns, and rheumatic disease activity. However, they tended to follow public health advice and continued therapy to mitigate the risk of COVID-19 diagnosis.

The risk of developing systemic lupus erythematosus (SLE) was reduced by 19% with every increase in a healthy lifestyle index score (HLIS). The risk of dsDNA positive SLE reduced 22% with the addition of each healthy behavior. Those with genetic risk factors may be able to reduce their risk of SLE diagnosis by almost 50% with adherence to healthy lifestyle behaviors.

Richard Furie, MD, discusses the recent FDA approval of anifrolumab-fnia for the treatment of patients with systemic lupus.

Researchers call for greater research on the relationship between PTSD and autoimmune diseases in Medicaid patients after finding a troubling association.